Biosciences

Banking

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023

February 6, 2023
Photo of Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023

[ad_1] INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $399 Million INGREZZA® (valbenazine) 2023 Net Product Sales Guidance of $1.67…

Read More »
Business

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

December 25, 2022
Photo of Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

[ad_1] This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of…

Read More »
Business

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

August 31, 2022

[ad_1] This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of…

Read More »
Back to top button
Close